Objective to re-examine measures to prevent oral mucositis caused by drugs in head and neck cancer patients during cancer treatment by measuring salivary excretion of 5-fluorouracil. Saliva, blood, and urine were simultaneously collected from oral cancer patients and breast cancer patient at the point in time of before, during, and after the administration of 5-FU, then the 5-FU levels of the samples were quantitatively analysed using LC-MS/MS. In all patients, the 5-FU levels in saliva and serum peaked at 30 min to 3 h after the start of 5-FU treatment, and high levels were maintained throughout the administration of the drug. With regard to urinary 5-FU levels, they remained high from 3 to 120 h after the start of 5-FU treatment. After the completion of 5-FU treatment, even though it not appeared in the patients’ serum and urine promptly, 5-FU was detected in saliva at 12 h after the completion of 5-FU treatment in one oral cancer patient and at 48 h after the completion of 5-FU treatment in the breast cancer patient. It was suggested that the level of hydration after the completion of chemotherapy may be involved in the differences in 5-FU excretion.

目的通过测量5-氟尿嘧啶的唾液排泄，重新检查预防头颈癌患者在药物治疗期间药物引起的口腔粘膜炎的措施。在施用5-FU之前，之中和之后的时间点同时从口腔癌患者和乳腺癌患者中收集唾液，血液和尿液，然后使用LC定量分析样品中5-FU的水平-MS / MS。在所有患者中，唾液和血清中5-FU的水平在开始5-FU治疗后30分钟至3小时达到峰值，并且在整个给药过程中都保持高水平。关于尿中5-FU的水平，在开始5-FU治疗后的3至120小时内它们一直保持较高水平。5-FU治疗结束后，即使没有立即出现在患者的血清和尿液中，一名口腔癌患者完成5-FU治疗后12小时和乳腺癌患者完成5-FU治疗后48小时在唾液中检测到5-FU。提示化疗完成后的水合作用水平可能与5-FU排泄的差异有关。